Novo Nordisk's Split Earnings Signal Leaves Investors Weighing a Buyback, a Guidance Lift and an Insider Sale
Published on 11/06/2026 at 06:01 | Editorial boerse-global.de
Novo Nordisk's third-quarter 2026 release landed with two profit figures pointing in opposite directions — and a share sale by its top scientist the same week gave shareholders one more data point to weigh. The stock fell 4.1% yesterday, though no specific trigger for that move has been established.
At the heart of the puzzle is the gap between the Danish drugmaker's adjusted and reported operating results. On a constant-currency basis, adjusted operating profit climbed 27%. Reported operating profit, measured the same way, fell 9%. Impairment charges of DKK 8.7 billion weighed on the reported line, according to Reuters.
Adjusted operating profit for the quarter came in at DKK 31,720 million. Revenue on the same basis totalled DKK 79,195 million, up 4% at constant exchange rates, with the Wegovy pill contributing DKK 5,394 million. The obesity franchise as a whole grew 22% — a pace that outstripped the group and offers a concrete marker for anyone betting the adjusted momentum can hold.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Guidance, too, hinges on which numbers you read. Novo Nordisk now expects both adjusted revenue and adjusted operating profit to land anywhere between 2% growth and a 2% decline in 2026, at constant currencies. The prior range ran from flat to a 6% drop. The lift moves the corridor in a friendlier direction, but a decline remains squarely inside it.
Adding to the mix, Executive Vice President and Chief Scientific Officer Martin Holst Lange sold 12,000 B-shares on Wednesday at DKK 285.00 apiece, according to media reports. The transaction pits a senior executive's selling against a company that just raised its outlook — a pairing that leaves the investment case resting less on the insider move itself than on whether the operating improvement carries through.
Capital returns tell a quieter story. Novo Nordisk has repurchased 41,714,179 B-shares for a cumulative DKK 11,564,364,801, part of a programme worth up to DKK 15 billion that began on 4 February 2026 and runs for twelve months. That ceiling is the planned envelope, not money already spent.
What comes next is a test of quality, not just quantity. Investors leaning optimistic will want the obesity business to keep expanding and that growth to flow through to earnings rather than revenue alone. The cautious camp has the reported figure on its side: impairments of DKK 8.7 billion are large enough to matter, and a persistent gap between adjusted and reported profit would undercut the bull case. Confirmation of the raised full-year target in subsequent quarterly figures — read across revenue growth, adjusted profit and the reported bottom line — is the catalyst that would settle the argument.
Ad
Novo Nordisk Stock: New Analysis - 6 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
